Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer

Cancer statistics in China and United States, 2022: profiles, trends, and determinants

(2022) Changfa Xia et al.   CHINESE MEDICAL JOURNAL

Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020

(2021) Wei Cao et al.   CHINESE MEDICAL JOURNAL

Cancer incidence and mortality in Zhejiang Province, Southeast China, 2016: a population-based study

(2021) You-Qing Wang et al.   CHINESE MEDICAL JOURNAL

Development and validation of a nomogram for predicting survival of breast cancer patients with ipsilateral supraclavicular lymph node metastasis

(2021) Min-Hao Lyu et al.   CHINESE MEDICAL JOURNAL

Interferon-gamma inhibits aldehyde dehydrogenasebright cancer stem cells in the 4T1 mouse model of breast cancer

(2021) Xiufen Zhuang et al.   CHINESE MEDICAL JOURNAL

Clinical practice guidelines for endoscopic breast surgery in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

(2021) Peng Tang et al.   CHINESE MEDICAL JOURNAL

UBE2C affects breast cancer proliferation through the AKT/mTOR signaling pathway

(2021) Zi-Nan Lu et al.   CHINESE MEDICAL JOURNAL

Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy

(2020) Yu-Ge Bai et al.   CHINESE MEDICAL JOURNAL

Breast cancer immunology and immunotherapy

(2020) Jing Zhao et al.   CHINESE MEDICAL JOURNAL

SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer

(2020) Lin Tang et al.   Oncogenesis

A Preliminary Study on the Establishment of the PDTX Model

(2020) Yong Liu et al.   Cancer Management and Research

Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy

(2020) A. Vera de Jonge et al.   Cancers

Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1

(2019) Yu Pan et al.   OncoImmunology

Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7

(2019) Shanhu Hu et al.   CANCER RESEARCH

High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer

(2019) Eriko Katsuta et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Expression of p27 and c-Myc by immunohistochemistry in breast ductal cancers in African American women

(2018) Farhan Khan et al.   Annals of Diagnostic Pathology

The MYC oncogene is a global regulator of the immune response

(2018) Stephanie C. Casey et al.   BLOOD

ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment

(2018) Hetal Patel et al.   MOLECULAR CANCER THERAPEUTICS

MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells

(2018) Jiahuan Zou et al.   MOLECULAR IMMUNOLOGY

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular alterations in triple-negative breast cancer—the road to new treatment strategies

(2017) Carsten Denkert et al.   LANCET

GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses

(2017) Zefang Tang et al.   NUCLEIC ACIDS RESEARCH

MYC: Master Regulator of Immune Privilege

(2017) Stephanie C. Casey et al.   TRENDS IN IMMUNOLOGY

The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)

(2017) Nobumoto Tomioka et al.   Breast Cancer

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer

(2016) Bo-Yong Wang et al.   Drug Design Development and Therapy

CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer

(2015) Yubao Wang et al.   CELL

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS

Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor

(2014) Camilla L. Christensen et al.   CANCER CELL

CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer

(2014) Edmond Chipumuro et al.   CELL

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles

(2014) Susanne Walz et al.   NATURE

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

MYC on the Path to Cancer

(2012) Chi V. Dang   CELL

Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma

(2012) Farhad Azimi et al.   JOURNAL OF CLINICAL ONCOLOGY

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE